IWM
ALXN

IHT Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

IHT Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-14
Closed -$2K – 1508
2018
Q1 		$2K Sell
14
-14
-50% -$1.67K ﹤0.01% 1546
2017
Q4 		$3K Hold
28
– – ﹤0.01% 1455
2017
Q3 		$4K Sell
28
-82
-75% -$11.1K ﹤0.01% 1136
2017
Q2 		$14 Hold
110
– – 0.01% 874
2017
Q1 		$13K Hold
110
– – 0.01% 770
2016
Q4 		$13K Buy
+110
New +$13.5K 0.01% 751

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

IHT Wealth Management's ALXN Position: Q2 2018 in Review

IHT Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 14 shares — an estimated $2K sold.

IHT Wealth Management first reported a position in ALXN in Q4 2016 and held it in 6 quarters. The position peaked at $13K in Q1 2017. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • IHT Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • IHT Wealth Management sold 14 Alexion Pharmaceuticals shares in Q2 2018, an estimated $2K.
  • IHT Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 6 quarters.
  • IHT Wealth Management's Alexion Pharmaceuticals position peaked at $13K in Q1 2017.
  • 600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.